Resources
News
October 30, 2023
AlivaMab Biologics Announces Two Bispecific Antibody Presentations at SITC 2023
Well-validated platforms for biologics discovery and engineering including T-cell engagers SAN DIEGO, Calif. – October 30, 2023 – AlivaMab Biologics, LLC (“AMB”), ...
October 16, 2023
AlivaMab Discovery Services Changes Name to AlivaMab Biologics, Reflecting Its Continuing Expansion and Evolution
Launching new and expanded capabilities providing end-to-end solutions in biologics discovery and engineering SAN DIEGO, Calif. – October 16, 2023 ...
April 10, 2023
AlivaMab Discovery Services Appoints Ankita Srivastava, PhD, as Vice President, Antibody Engineering and Protein Sciences
Veteran with breadth and depth of multispecific antibody drug discovery to evolve ADS’ capabilities SAN DIEGO, Calif. – April 10, ...
November 15, 2022
Ablexis and AlivaMab Discovery Services Announce Expansion of Antibody Drug Discovery and Engineering Capabilities
New platforms and capabilities further enable partners to advance better antibody drugs faster. SAN DIEGO, Calif. – November 15, 2022 ...
September 23, 2022
AlivaMab Discovery Services Reappoints Dr. Larry Green as Chief Executive Officer
SAN DIEGO, Calif. – September 23, 2022 – AlivaMab Discovery Services (“ADS”), a leader in the discovery of superior antibody-based ...
January 31, 2022
Ablexis and AlivaMab Discovery Services Announce Agreements with Almirall to Accelerate Antibody Drug Discovery and Development
Ablexis’ multi-target licensing agreement grants Almirall rights to use the AlivaMab® Mouse technology for research, development and commercialization of antibodies ...
January 11, 2022
AlivaMab Discovery Services Appoints Jane Seagal, PhD, as Vice President of Antibody Discovery
AbbVie veteran to support rapid growth and new technologies. SAN DIEGO, Calif. – January 11, 2022 – AlivaMab Discovery Services (“ADS”), a ...
November 1, 2021
AlivaMab Discovery Services Expands Discovery Agreement with IGM Biosciences
Expanded agreement aims to accelerate the discovery of next-generation antibody modalities SAN DIEGO, Calif. – November 1, 2021 – AlivaMab Discovery ...
September 14, 2021
AlivaMab Discovery Services Announces Multi-Target Agreement with Teva Pharmaceuticals
Agreement aims to accelerate the discovery of new therapeutics SAN DIEGO, Calif. – September 14, 2021 – AlivaMab Discovery Services (“ADS”), a ...
December 14, 2020
AlivaMab Discovery Services Expands Drug Discovery Platform into Developability Assessment
Expansion gives AlivaMab Discovery Services the ability to streamline the transition of drug discovery programs into development SAN DIEGO, Calif ...
June 3, 2020
AlivaMab Discovery Services (ADS) Announces Agreement with Tanabe Research Laboratories USA
ADS announces integrated antibody drug discovery collaboration SAN DIEGO, Calif. – June 3, 2020 – AlivaMab Discovery Services, LLC, a ...
April 22, 2020
Ablexis, AlivaMab Discovery Services, and Berkeley Lights Collaborate to Identify a Diverse Panel of Anti-SARS-CoV-2 Human Antibodies
Offers unique resources for COVID-19 therapeutic discovery SAN DIEGO and EMERYVILLE, Calif. – April 22, 2020 – Ablexis, LLC, AlivaMab ...
September 16, 2019
AlivaMab Discovery Services Announces Multi-Target Agreement with Janssen
ADS to provide expertise and capabilities in antibody drug discovery SAN DIEGO, Calif. – September 16, 2019 – AlivaMab Discovery ...
February 26, 2019
AlivaMab Discovery Services Identifies Highly Potent Antibodies in Two Months for Inaugural Client Project
Company Expands Team with Veterans of Antibody Discovery and Development SAN DIEGO, Calif. – February 26, 2019 – AlivaMab ...
Case Studies
From Novel Assay Development to Quality Therapeutic Leads on a Rapid Timeline
This case study details AlivaMab Biologics delivering high affinity antibody drug candidates for a virtual client.
Breaking Immune Tolerance to Generate Highly Potent Cross-Reactive Antibodies
This case study shows AlivaMab Biologics breaking immune tolerance to create antibodies against conserved targets.
Generating Diverse Antibodies Against Multi-Spanning Membrane Protein Targets
This case study demonstrates how AlivaMab Biologics can overcome challenges of membrane protein drug development.